Evelo Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Evelo Biosciences

18/05/2023 19:34

* Evelo Biosciences Inc  EVLO.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 16 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Evelo Biosciences Inc's reported EPS for the quarter was a
loss
of 23 cents​.
    * The mean earnings estimate of analysts had risen by
about 22.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Evelo Biosciences Inc shares had fallen by 22.5% this
quarter and lost 91.3% so far this year.
    * The company reported a quarterly loss of $25.34 million.
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $1.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
18 at 06:34 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.16          -0.23          Missed
 Dec. 31 2022      -0.28          -0.21          Beat
 Sep. 30 2022      -0.33          -0.28          Beat
 Jun. 30 2022      -0.43          -0.40          Beat